Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of antidiabetic drugs developed over the past 15 years. GLP-1, a gastrointestinal peptide hormone that contributes to the postprandial “incretin effect”, stimulates glucose-dependent insulin secretion. The i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovich
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2017
Materias:	diabetes mellitus, type 2 glucagon-like peptide-1 glucagon-like peptide-1 receptor hypoglycemic agents incretins Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/a1353861504246f5877ed418350e4d42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a1353861504246f5877ed418350e4d42
record_format	dspace
spelling	oai:doaj.org-article:a1353861504246f5877ed418350e4d422021-11-14T09:00:21ZEvolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes2072-03512072-037810.14341/DM8804https://doaj.org/article/a1353861504246f5877ed418350e4d422017-10-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/8804https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of antidiabetic drugs developed over the past 15 years. GLP-1, a gastrointestinal peptide hormone that contributes to the postprandial “incretin effect”, stimulates glucose-dependent insulin secretion. The incretin effect is greatly diminished in type 2 diabetes, but can be restored by GLP-1RAs. These drugs also exert other GLP-1 effects, including reducing glucagon secretion, delaying gastric emptying, reducing food intake, improving cardiac ventricular function, and lowering blood pressure. Short-acting GLP-1RAs are administered once daily (lixisenatide) or twice daily (exenatide); long-acting GLP 1RAs are administered once daily (liraglutide) or once weekly (slow-release exenatide, dulaglutide, albiglutide). All GLP-1RAs significantly reduce glycated hemoglobin (HbA1c) in patients with type 2 diabetes whose glycemic control is inadequate with oral antidiabetic drugs. Compared with other antidiabetic medications, GLP-1RAs provide better glycemic control with the additional benefit of weight loss. Within this class, long-acting GLP-1RAs are more efficacious than short-acting GLP-1RAs, with similar or lower risk of hypoglycemia and lower incidence of gastrointestinal adverse effects. Head-to-head trials and a network meta-analysis suggest that once daily liraglutide is the most effective GLP-1RA in reducing HbA1c. Dulaglutide is the only once-weekly GLP 1RA demonstrated to be noninferior to liraglutide. The once-weekly GLP-1RAs offer additional advantages to patients, including fewer injections and easy-to-use, single-dose pen devices. Despite the relatively recent development of GLP-1RAs, international diabetes guidelines recognize the benefits of this class of drugs and recommend them as a treatment option for patients with type 2 diabetes.Gagik R. GalstyanEvgeniya A. KarataevaEkaterina A. YudovichEndocrinology Research Centrearticlediabetes mellitus, type 2glucagon-like peptide-1glucagon-like peptide-1 receptorhypoglycemic agentsincretinsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 20, Iss 4, Pp 286-298 (2017)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus, type 2 glucagon-like peptide-1 glucagon-like peptide-1 receptor hypoglycemic agents incretins Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus, type 2 glucagon-like peptide-1 glucagon-like peptide-1 receptor hypoglycemic agents incretins Nutritional diseases. Deficiency diseases RC620-627 Gagik R. Galstyan Evgeniya A. Karataeva Ekaterina A. Yudovich Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
description	Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of antidiabetic drugs developed over the past 15 years. GLP-1, a gastrointestinal peptide hormone that contributes to the postprandial “incretin effect”, stimulates glucose-dependent insulin secretion. The incretin effect is greatly diminished in type 2 diabetes, but can be restored by GLP-1RAs. These drugs also exert other GLP-1 effects, including reducing glucagon secretion, delaying gastric emptying, reducing food intake, improving cardiac ventricular function, and lowering blood pressure. Short-acting GLP-1RAs are administered once daily (lixisenatide) or twice daily (exenatide); long-acting GLP 1RAs are administered once daily (liraglutide) or once weekly (slow-release exenatide, dulaglutide, albiglutide). All GLP-1RAs significantly reduce glycated hemoglobin (HbA1c) in patients with type 2 diabetes whose glycemic control is inadequate with oral antidiabetic drugs. Compared with other antidiabetic medications, GLP-1RAs provide better glycemic control with the additional benefit of weight loss. Within this class, long-acting GLP-1RAs are more efficacious than short-acting GLP-1RAs, with similar or lower risk of hypoglycemia and lower incidence of gastrointestinal adverse effects. Head-to-head trials and a network meta-analysis suggest that once daily liraglutide is the most effective GLP-1RA in reducing HbA1c. Dulaglutide is the only once-weekly GLP 1RA demonstrated to be noninferior to liraglutide. The once-weekly GLP-1RAs offer additional advantages to patients, including fewer injections and easy-to-use, single-dose pen devices. Despite the relatively recent development of GLP-1RAs, international diabetes guidelines recognize the benefits of this class of drugs and recommend them as a treatment option for patients with type 2 diabetes.
format	article
author	Gagik R. Galstyan Evgeniya A. Karataeva Ekaterina A. Yudovich
author_facet	Gagik R. Galstyan Evgeniya A. Karataeva Ekaterina A. Yudovich
author_sort	Gagik R. Galstyan
title	Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
title_short	Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
title_full	Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
title_fullStr	Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
title_full_unstemmed	Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
title_sort	evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
publisher	Endocrinology Research Centre
publishDate	2017
url	https://doaj.org/article/a1353861504246f5877ed418350e4d42
work_keys_str_mv	AT gagikrgalstyan evolutionofglucagonlikepeptide1receptoragonistsforthetreatmentoftype2diabetes AT evgeniyaakarataeva evolutionofglucagonlikepeptide1receptoragonistsforthetreatmentoftype2diabetes AT ekaterinaayudovich evolutionofglucagonlikepeptide1receptoragonistsforthetreatmentoftype2diabetes
_version_	1718429548894224384

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes

Ejemplares similares